Research Footnotes

Patients Page
  1. Hall, W. What does the history of Australian cannabis policy suggest about its likely future shape? The University of Queensland Centre for Clinical Research [online]. Available from: https://www.academia.edu/2867399/What_does_the_history_of_Australian_cannabis_policy_suggest_about_its_likely_future_shape [accessed 15 August 2021].
  2. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/12648025/ [accessed 15 August 2021].
  3. GW Pharma. (2012). Sativex Product Monograph. Available from: https://pdf.hres.ca/dpd_pm/00016162.PDF [accessed 15 August 2021].

Healthcare Professionals Portal
  1. ElSohly, M., Gul, W. (2014). Constituents of cannabis sativa. Handbook of Cannabis [online]. Available from: https://oxford.universitypressscholarship.com/view/10.1093/acprof:oso/9780199662685.001.0001/acprof-9780199662685 [accessed 15 August 2021].
  2. Matsuda L., et al. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/2165569/ [accessed 15 August 2021].
  3. Pertwee, R. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219532/ [accessed 15 August 2021].
  4. U.S. Food & Drug Administration. (2018). FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms [accessed 15 August 2021].
  5. Bergamaschi, M., et al. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/ [accessed 15 August 2021].
  6. Niesink, R., van Laar, M. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Frontiers in Psychiatry [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797438/ [accessed 15 August 2021].
  7. Boehnke, K., et al. (2019). Qualifying Conditions of Medical Cannabis License Holders in the United States. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398594/ [accessed 15 August 2021].
  8. National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425767/#_ncbi_dlg_citbx_NBK425767 [accessed 15 August 2021].‍
  9. ‍Russo, E. (2016). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/27179600/ [accessed 15 August 2021].
  10. Lu, H, and Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/26698193/ [accessed 15 August 2021].
  11. Scholastic. (2011). The Science of the Endocannabinoid System: How THC Affects the Brain and the Body. Available from: http://headsup.scholastic.com/students/endocannabinoid [accessed 15 August 2021].
  12. Argenziano, M. et al. (2019). The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. International Journal of Molecular Sciences [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928713/ [accessed 15 August 2021].
  13. Farokhnia, M., et al. (2020). Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational Psychiatry [online]. Available from: https://www.researchgate.net/publication/339384908_Effects_of_oral_smoked_and_vaporized_cannabis_on_endocrine_pathways_related_to_appetite_and_metabolism_a_randomized_double-blind_placebo-controlled_human_laboratory_study [accessed 15 August 2021].
  14. Russo, E. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal Pharmacology [online]. Available from: https://www.researchgate.net/publication/51485891_Taming_THC_Potential_cannabis_synergy_and_phytocannabinoid-terpenoid_entourage_effects [accessed 15 August 2021].
  15. Mechoulam, R. (2012). Cannabis—A Valuable Drug That Deserves Better Treatment. Mayo Clinic Proceedings [online]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498425/ [accessed 15 August 2021].
  16. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/12648025/ [accessed 15 August 2021].
  17. GW Pharma. (2012). Sativex Product Monograph. Available from: https://pdf.hres.ca/dpd_pm/00016162.PDF [accessed 15 August 2021].

Product Information for Patients
  1. Hudson, R, et al. (2019). Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation. The Journal of Neuroscience [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/31570536/ [accessed 19 August 2021].
  2. Health Canada. (2018). Information for Health Care Professionals- Cannabis (marihuana, marijuana) and the cannabinoids. Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf [accessed 19 August 2021].
  3. MacCallum, C., Russo, E. (2018). Practical Considerations in Medical Cannabis Administration and Dosing. European Journal of Internal Medicine [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/29307505/ [accessed 19 August 2021].

Kind Medical acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

HOMEPatientsproductsAbout
PHARMACISTSDoctorsEDUCATION
HCP PortalFAQsContact
1800-KIND-HI | (1800 5463 44)
We are available by phone Monday to Friday from 9am to 5pm AWST.
© All Rights Reserved.
TERMSprivacy